A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma

Protocol No
PRECOG-PRE0404
Principal Investigator
Mehdi Hamadani
Phase
I/II
Summary
Ibrutinib has been approved by the Food and Drug Administration (FDA) as treatment for patients with mantle cell lymphoma who have received at least one prior therapy. Ixazomib is in a class of medications called proteasome inhibitors. Cancer cells depend on proteasome to provide this protein metabolism (turnover) function to regulate their growth and survival. Ixazomib disrupts a cancer cells ability to survive by blocking the proteasome and disrupting protein metabolism. This may help to slow down the growth of cancer or may cause cancer cells to die. Ixazomib in combination with two other anti-cancer drugs (lenalidomide and dexamethasone) has been approved by the FDA in patients with multiple myeloma who have received at least one prior therapy. However, ixazomib has not been approved by the FDA for treatment of mantle cell lymphoma, and its use in this study is considered investigational.
Description
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma (PrE0404)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: